<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CTJ</journal-id>
<journal-id journal-id-type="hwp">spctj</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Trials</journal-id>
<journal-title>Clinical Trials</journal-title>
<issn pub-type="ppub">1740-7745</issn>
<issn pub-type="epub">1740-7753</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1740774512453520</article-id>
<article-id pub-id-type="publisher-id">10.1177_1740774512453520</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Novel incentive-based approaches to adherence</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Kimmel</surname><given-names>Stephen E</given-names></name>
<xref ref-type="aff" rid="aff1-1740774512453520">a</xref>
<xref ref-type="aff" rid="aff2-1740774512453520">b</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Troxel</surname><given-names>Andrea B</given-names></name>
<xref ref-type="aff" rid="aff1-1740774512453520">a</xref>
<xref ref-type="aff" rid="aff3-1740774512453520">c</xref>
</contrib>
</contrib-group>
<aff id="aff1-1740774512453520"><label>a</label>Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA</aff>
<aff id="aff2-1740774512453520"><label>b</label>Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA</aff>
<aff id="aff3-1740774512453520"><label>c</label>Center for Health Incentives and Behavioral Economics, Leonard Davis Institute, University of Pennsylvania, Philadelphia, PA, USA</aff>
<author-notes>
<corresp id="corresp1-1740774512453520">Andrea B Troxel, Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, 632 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6021, USA. Email: <email>atroxel@mail.med.upenn.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>12</month>
<year>2012</year>
</pub-date>
<volume>9</volume>
<issue>6</issue>
<issue-title>University of Pennsylvania Conference on Statistical Issues in Clinical Trials: Emerging statistical issues in the conduct and monitoring of clinical trials</issue-title>
<fpage>689</fpage>
<lpage>695</lpage>
<permissions>
<copyright-statement>© The Author(s), 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">The Society for Clinical Trials</copyright-holder>
</permissions>
<abstract>
<sec id="section1-1740774512453520">
<title>Background</title>
<p>Adherence to medications for chronic conditions is often very low, limiting the benefit to patients, even when the medications are effective and have favorable side effect profiles.</p>
</sec>
<sec id="section2-1740774512453520">
<title>Purpose</title>
<p>This article reviews some of the prior work on treatment adherence, introduces novel concepts from behavioral economics that can be used to design interventions to improve adherence, and proposes new approaches for clinical trials.</p>
</sec>
<sec id="section3-1740774512453520">
<title>Methods</title>
<p>Relevant experience of the authors and insights from the literature were combined to identify key issues and propose methodological improvements. Specific examples regarding adherence to warfarin are provided.</p>
</sec>
<sec id="section4-1740774512453520">
<title>Results</title>
<p>Several new approaches to trial design can be effectively applied in the context of medication adherence. These include tailored intervention strategies and sequential multiple assignment randomized trial (SMART) designs.</p>
</sec>
<sec id="section5-1740774512453520">
<title>Limitations</title>
<p>While we have proposed to use these new approaches for ongoing studies of adherence in behavioral health, practical experience with their application is still somewhat limited.</p>
</sec>
<sec id="section6-1740774512453520">
<title>Conclusions</title>
<p>Behavioral economics offer a variety of concepts that, when used in the design of interventions to improve adherence, may be more successful than traditional approaches. New clinical trial designs can also be adopted to improve the efficiency of studies that assess these approaches.</p>
</sec>
</abstract>
</article-meta>
</front>
<body>
<sec id="section7-1740774512453520" sec-type="intro">
<title>Introduction</title>
<p>Adherence to medication use in many chronic conditions is suboptimal. For example, clinical practice guidelines recommend the use of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) to lower cholesterol [<xref ref-type="bibr" rid="bibr1-1740774512453520">1</xref>] and clinical trials have shown that statins lower the risk of acute myocardial infarction by about 30% [<xref ref-type="bibr" rid="bibr2-1740774512453520">2</xref><xref ref-type="bibr" rid="bibr3-1740774512453520"/><xref ref-type="bibr" rid="bibr4-1740774512453520"/><xref ref-type="bibr" rid="bibr5-1740774512453520"/><xref ref-type="bibr" rid="bibr6-1740774512453520"/>–<xref ref-type="bibr" rid="bibr7-1740774512453520">7</xref>]. Despite their clear benefits and tolerable side effect profile, patient adherence to statins is moderate at best: within a year of being prescribed statins, approximately half of the patients have discontinued use [<xref ref-type="bibr" rid="bibr8-1740774512453520">8</xref><xref ref-type="bibr" rid="bibr9-1740774512453520"/><xref ref-type="bibr" rid="bibr10-1740774512453520"/><xref ref-type="bibr" rid="bibr11-1740774512453520"/><xref ref-type="bibr" rid="bibr12-1740774512453520"/><xref ref-type="bibr" rid="bibr13-1740774512453520"/><xref ref-type="bibr" rid="bibr14-1740774512453520"/><xref ref-type="bibr" rid="bibr15-1740774512453520"/><xref ref-type="bibr" rid="bibr16-1740774512453520"/>–<xref ref-type="bibr" rid="bibr17-1740774512453520">17</xref>]. Poor adherence leads to adverse outcomes, higher hospitalization and mortality rates, and increased health-care costs in patients with cardiovascular disease [<xref ref-type="bibr" rid="bibr8-1740774512453520">8</xref>,<xref ref-type="bibr" rid="bibr9-1740774512453520">9</xref>,<xref ref-type="bibr" rid="bibr16-1740774512453520">16</xref><xref ref-type="bibr" rid="bibr17-1740774512453520"/><xref ref-type="bibr" rid="bibr18-1740774512453520"/><xref ref-type="bibr" rid="bibr19-1740774512453520"/><xref ref-type="bibr" rid="bibr20-1740774512453520"/><xref ref-type="bibr" rid="bibr21-1740774512453520"/>–<xref ref-type="bibr" rid="bibr22-1740774512453520">22</xref>].</p>
<p>Similarly, warfarin is recommended for prevention of thromboembolism (TE) [<xref ref-type="bibr" rid="bibr23-1740774512453520">23</xref>]. Warfarin, when properly used, is highly efficacious, reducing the risk of embolic events in atrial fibrillation by 68% overall and 85% in patients older than 75 with at least one other risk factor for stroke [<xref ref-type="bibr" rid="bibr24-1740774512453520">24</xref>] and has been shown to be superior to aspirin [<xref ref-type="bibr" rid="bibr24-1740774512453520">24</xref><xref ref-type="bibr" rid="bibr25-1740774512453520"/><xref ref-type="bibr" rid="bibr26-1740774512453520"/><xref ref-type="bibr" rid="bibr27-1740774512453520"/>–<xref ref-type="bibr" rid="bibr28-1740774512453520">28</xref>]. Despite its proven benefits, poor levels of anticoagulation (AC) (measured by the international normalized ratio (INR)) with warfarin therapy are common. Specialized, standard-of-care AC clinics devoted to monitoring patients on warfarin have been shown to improve levels of AC and decrease complication rates [<xref ref-type="bibr" rid="bibr29-1740774512453520">29</xref>]; however, even in these clinics, 32%–68% of patient time is spent out of the target therapeutic range for the INR [<xref ref-type="bibr" rid="bibr27-1740774512453520">27</xref>,<xref ref-type="bibr" rid="bibr28-1740774512453520">28</xref>,<xref ref-type="bibr" rid="bibr30-1740774512453520">30</xref>,<xref ref-type="bibr" rid="bibr31-1740774512453520">31</xref>]. Patients who have high or low (i.e., out-of-range) INRs must be carefully reassessed within a short period and often need dosage changes. This generates additional clinic visits, blood tests, and potential for miscalculations of dosage needs [<xref ref-type="bibr" rid="bibr32-1740774512453520">32</xref>,<xref ref-type="bibr" rid="bibr33-1740774512453520">33</xref>]. The costs associated with the loss of AC include increased warfarin-related visits to emergency rooms and hospitalizations [<xref ref-type="bibr" rid="bibr3-1740774512453520">3</xref>] and more frequent follow-up [<xref ref-type="bibr" rid="bibr33-1740774512453520">33</xref>]. Inadequate regulation of AC is even common in clinical trials [<xref ref-type="bibr" rid="bibr27-1740774512453520">27</xref>,<xref ref-type="bibr" rid="bibr30-1740774512453520">30</xref>,<xref ref-type="bibr" rid="bibr34-1740774512453520">34</xref>]. Inadequate regulation can lead to lack of effectiveness of the drug (during periods of underanticoagulation) and to side effects from overanticoagulation [<xref ref-type="bibr" rid="bibr27-1740774512453520">27</xref>,<xref ref-type="bibr" rid="bibr28-1740774512453520">28</xref>,<xref ref-type="bibr" rid="bibr30-1740774512453520">30</xref>,<xref ref-type="bibr" rid="bibr34-1740774512453520">34</xref>]. Among patients followed longer term, the cumulative incidence of major bleeding at 4 years ranges from 17% to 25% [<xref ref-type="bibr" rid="bibr35-1740774512453520">35</xref><xref ref-type="bibr" rid="bibr36-1740774512453520"/>–<xref ref-type="bibr" rid="bibr37-1740774512453520">37</xref>]. Thus, in many areas, improvements in medication adherence would be associated with improvements in health outcomes and decreases in the costs of medical care. Despite this, improving medication adherence has been challenging.</p>
<p>The issue of adherence applies to many different contexts. Here, we focus primarily on adherence to a specific treatment regimen in general clinical practice, but much of what we discuss is relevant to adherence to treatment within clinical trials and adherence to clinical trials protocols themselves. Many of the same kinds of interventions can be applied in multiple contexts. We will point this out where relevant, while focusing most on adherence to medications as prescribed by caregivers in a real-world setting.</p>
</sec>
<sec id="section8-1740774512453520">
<title>Behavioral economics and interventions for adherence</title>
<sec id="section9-1740774512453520">
<title>Financial incentives</title>
<p>Different kinds of financial incentives have been proposed as mechanisms to improve adherence. Copayment reduction or elimination is an important component of value-based insurance design (VBID) [<xref ref-type="bibr" rid="bibr38-1740774512453520">38</xref>], in which structural changes are made to try to improve the rate of medication possession and consequently adherence. Several studies have assessed whether reducing prescription copayments for long-term medications can improve adherence. This idea stemmed from an observational study in which adherence worsened in patients who were subject to increases in copayments for prescription fills and refills [<xref ref-type="bibr" rid="bibr39-1740774512453520">39</xref>]. This study also showed general reductions in adherence over time for all subjects, however, indicating that temporal trends may have driven this effect in part. In addition, the effects of copayment increases versus reductions appear to be asymmetric, in that increases in copayments do have a detrimental effect on adherence, while reductions in copayments may not have comparable benefit [<xref ref-type="bibr" rid="bibr40-1740774512453520">40</xref>]. This is likely due to the difference in perception of losses versus gains: the concept of ‘loss aversion’ describes the phenomenon in which people experience more disutility, or lack of satisfaction, from the loss of a given dollar amount than the degree of positive utility from a gain of the same dollar amount [<xref ref-type="bibr" rid="bibr41-1740774512453520">41</xref>]. These and other observations have led to the development of other interventions based on behavioral economic concepts, such as financial incentives.</p>
<p>Incentives have been shown to affect the rate of healthy behaviors in various contexts, including utilization rates of beneficial services such as follow-up for abnormal pap smears [<xref ref-type="bibr" rid="bibr42-1740774512453520">42</xref>], postpartum visits to health professionals by adolescents [<xref ref-type="bibr" rid="bibr43-1740774512453520">43</xref>], and purified protein derivative (PPD) test-reading return rates in HIV patients [<xref ref-type="bibr" rid="bibr44-1740774512453520">44</xref>]. A review of 11 randomized trials of financial incentives found that in 10 studies, financial incentives promoted adherence better than any tested alternative, leading to better blood pressure control, appointment attendance, and higher immunization rates. A more recent review of 47 studies of economic incentives found that various incentive mechanisms were effective in changing behavior. Effectiveness varied based on the magnitude and type of the payment, but few studies examined either longer term effects or cost-effectiveness [<xref ref-type="bibr" rid="bibr45-1740774512453520">45</xref>].</p>
<p>The literature most relevant to warfarin interventions is that which demonstrates modification of health behaviors for chronic diseases. Studies on the effects of financial incentives on unhealthy behaviors such as alcohol or cocaine use [<xref ref-type="bibr" rid="bibr46-1740774512453520">46</xref>] are thus of interest, as such behaviors are difficult to change and require ongoing reinforcement. In controlled settings such as drug treatment programs, financial incentives have been highly effective in modifying behavior and have led to higher rates of program retention and abstinence [<xref ref-type="bibr" rid="bibr47-1740774512453520">47</xref>]. This strategy, known in the literature as contingency management [<xref ref-type="bibr" rid="bibr46-1740774512453520">46</xref>,<xref ref-type="bibr" rid="bibr48-1740774512453520">48</xref>], can substantially improve the rate of healthy behaviors. For example, one randomized clinical trial (RCT) among cocaine-using adults found that the payment of progressively larger incentives for serial negative urine samples (total potential value of the incentive was $997.50) led to significant improvements in treatment completion and abstinence [<xref ref-type="bibr" rid="bibr47-1740774512453520">47</xref>]. This effect continued beyond the period of financial incentives. This study is illustrative of the literature because it shows clear effectiveness of incentives and also demonstrates that frequent monitoring and feedback may be important.</p>
<p>Lottery-based incentives have also shown promise in the literature as a means of altering health behaviors [<xref ref-type="bibr" rid="bibr45-1740774512453520">45</xref>,<xref ref-type="bibr" rid="bibr49-1740774512453520">49</xref>]. This approach was inspired by the success of the Dutch postal code lottery, in which winning postal codes are selected, and those living within the code who purchased a ticket receive a prize [<xref ref-type="bibr" rid="bibr50-1740774512453520">50</xref>]. A number of insights from behavioral economics combine to both explain the success of lotteries and suggest ways of maximizing their effectiveness. First, consistent with research showing that even small rewards and punishments can have great incentive value if they occur immediately [<xref ref-type="bibr" rid="bibr51-1740774512453520">51</xref><xref ref-type="bibr" rid="bibr52-1740774512453520"/><xref ref-type="bibr" rid="bibr53-1740774512453520"/>–<xref ref-type="bibr" rid="bibr54-1740774512453520">54</xref>], adherent patients can receive rapid feedback about whether they won. Second, based on research showing that people are motivated by the experience of past rewards and the prospect of future rewards [<xref ref-type="bibr" rid="bibr55-1740774512453520">55</xref>], and on research showing that people are particularly emotionally attracted to small probabilities of large rewards [<xref ref-type="bibr" rid="bibr56-1740774512453520">56</xref>], lotteries can be tailored to provide frequent small payoffs (e.g., a 1 in 5 chance at a $10 reward) and infrequent large payoffs (e.g., a 1 in 100 chance at a $100 reward). The frequent small payoffs increase the attractiveness of lotteries by giving lottery players intermittent positive reinforcement, also called variable reinforcement. Third, research on decision making has found that the desire to avoid regret is a potent force in decision making under risk [<xref ref-type="bibr" rid="bibr57-1740774512453520">57</xref>], so by giving nonadherent patients feedback about what they <italic>would have</italic> won had they been adherent, the incentive scheme can be designed to maximize the threat of regret in people who fail to adhere. In the Dutch postal code lottery, those who fail to purchase a ticket learn that they would have won had they purchased a ticket; similarly, nonadherent patients can be informed that they would have won a prize had they been adherent. Anticipated regret has also been shown in other contexts to affect preventive behavior, such as the significant increase in vaccination use among people who experienced the regret of failing to get vaccinated in the prior year and then getting sick [<xref ref-type="bibr" rid="bibr58-1740774512453520">58</xref>]. Finally, the possibility of losing money that one could have won as a result of nonadherence also plays on loss aversion [<xref ref-type="bibr" rid="bibr40-1740774512453520">40</xref>]. Loss aversion has been used to explain many inconsistencies in traditional economic choice models and has improved understanding of areas that involve choice under conditions of uncertainty ranging from investment choices [<xref ref-type="bibr" rid="bibr59-1740774512453520">59</xref>] to physician behavior in response to reductions in income [<xref ref-type="bibr" rid="bibr60-1740774512453520">60</xref>].</p>
</sec>
<sec id="section10-1740774512453520">
<title>Other behavioral interventions for adherence</title>
<p>Electronic reminder systems have also been studied to improve adherence, since among the reasons patients cite for poor adherence are forgetfulness, other priorities, a decision to omit doses, lack of information, and emotional factors [<xref ref-type="bibr" rid="bibr61-1740774512453520">61</xref>]. Successful programs for improving adherence share four common characteristics: (1) they provide information regarding the illness, (2) they use prompts and reminders, (3) they provide positive reinforcement for adherence, and (4) they provide social support for treatment [<xref ref-type="bibr" rid="bibr62-1740774512453520">62</xref>]. Using environmental supports to cue and reinforce taking medication, such as pill containers or watches with alarms, calendars to increase appointment attendance, and notebooks for recording side effects, have been found to be among the most effective strategies for individuals with chronic illnesses [<xref ref-type="bibr" rid="bibr63-1740774512453520">63</xref><xref ref-type="bibr" rid="bibr64-1740774512453520"/>–<xref ref-type="bibr" rid="bibr65-1740774512453520">65</xref>]. Electronic technology can be used to identify medication use, prompt users to take medication, record when containers are opened, alert patients if they are taking the wrong medication or taking it at the wrong time, and automatically download data to a secure website. If problematic adherence is identified, electronic devices can also provide feedback to patients to remind them of important personal goals enhanced by taking medication as prescribed. Thus, electronic devices combine educational, behavioral, and affective strategies. This technology allows for adherence feedback to be provided frequently to large numbers of patients without the associated cost of hiring case managers or home nurses.</p>
</sec>
</sec>
<sec id="section11-1740774512453520">
<title>A randomized trial in warfarin adherence</title>
<p>The concepts described above led to the design of a randomized controlled trial, currently ongoing (National Institutes of Health (NIH) R01-HL090929), to improve AC in patients taking warfarin. Two small pilot trials first tested the feasibility and effectiveness of a lottery-based intervention, with promising results. Both pilot studies used a prepost-intervention design in a small sample of 10 subjects; the first pilot implemented a lottery with a daily expected value of $5, while the second used a daily expected value of $3. In both pilots, the rate of nonadherence was drastically lower after the introduction of the lottery, from about 20%–25% under usual care to about 2%–3% while the lottery was ongoing. The present study includes patients at the AC clinics of the Hospital of the University of Pennsylvania and the Philadelphia Veterans Affairs Medical Center who are randomized evenly to four arms: a lottery intervention with the features described above and an expected value of $3 per day; an electronic pillbox/reminder system (the Med-eMonitor [<xref ref-type="bibr" rid="bibr66-1740774512453520">66</xref>]); the lottery combined with the Med-eMonitor; and a control arm, in which the Med-eMonitor is activated only to record adherence (i.e., pill taking) but does not provide any reminders or feedback. The study’s primary outcome is repeated assessment of INR at monthly intervals for six months, with each assessment designated as in-range or out-of-range. The goal of the study is to identify an intervention that will improve adherence and INR outcomes while being scalable to clinical practice outside the context of a randomized trial. We are also aware, however, of the potential for nonadherence with study procedures such as clinic visits and INR measurements, and thus included participation payments, separate from the trial interventions and constant across all study arms, to encourage compliance with scheduled study encounters. With a planned sample size of 268 subjects, the study was designed to accommodate five hypotheses of interest: comparison of each active arm to the control arm, and comparison of the combined lottery/monitor arm to the lottery-only arm and the monitor-only arm. We used a two-sided type I error rate of 0.01 using a Bonferroni correction for the five multiple comparisons, and required 80% power to detect a 30% reduction in the rate of out-of-range INRs, assuming an average of seven assessments per subject, an intra-class correlation (ICC) of 0.05 (based on an estimated ICC of 0.05 from a prior prospective cohort study in the same patient population), and 10% dropout by 6 months. Analyses will be conducted on the repeated INR assessment using a generalized linear mixed model with a logit link, random intercept and slope effects, and time by treatment interaction terms to test the primary hypotheses. Accrual is complete and final follow-up is ongoing and expected to be completed by early summer 2012.</p>
</sec>
<sec id="section12-1740774512453520">
<title>Two new approaches to trial design</title>
<p>Two concepts – targeting and tailoring – can be applied effectively in the context of interventions for adherence, both to allow more and different kinds of interventions to be rigorously assessed and to improve the efficiency of clinical trials. These are discussed below.</p>
<sec id="section13-1740774512453520">
<title>Targeting</title>
<p>Targeting, also sometimes called segmenting, is simply the concept of aiming the interventions at those most likely to benefit from them. For example, most strategies to improve adherence need only be applied to nonadherent subjects; in our warfarin trial, based on pilot data, we restrict the population to those who have out-of-range INRs at baseline or have been out of range at least once in the last three months. Subjects who are in range over a 3-month period are presumably compliant enough with their warfarin dosing that improving their adherence slightly is not likely to result in clinical improvements. In other contexts, interventions can be targeted to subjects in different ways. For example, a program aimed at helping subjects quit smoking might be targeted to those who express significant motivation for quitting, as assessed using the Prochaska scale for stages of change [<xref ref-type="bibr" rid="bibr67-1740774512453520">67</xref>,<xref ref-type="bibr" rid="bibr68-1740774512453520">68</xref>].</p>
</sec>
<sec id="section14-1740774512453520">
<title>Tailoring</title>
<p>Tailoring is a more sophisticated approach that can be implemented in a number of ways. The main idea is to develop interventions that address each individual’s needs and issues rather than applying a ‘one size fits all’ approach. In the context of medication adherence, patients cite different reasons for their lack of compliance with pill taking. For some, forgetfulness is a big issue. For others, the problem is a lack of understanding of the benefits of the medication; this is a particular problem for ‘silent’ conditions such as atrial fibrillation (often silent and a major indication for warfarin), hypertension, hypercholesterolemia, and others in which the patients do not experience daily symptoms as a result of their condition. For still others, cost may be the primary barrier. In this scenario, a tailored approach would implement different interventions addressing each of these issues. An automated reminder system would combat forgetfulness and distraction, an education program with reminders of the long-term benefits could address the lack of motivation, and a financial incentive can counteract the problem of cost.</p>
<p>Several options exist for implementation and rigorous evaluation of tailored strategies. Given the many biases that exist in observational studies, maintaining comparability of intervention groups via randomization is desirable. This can be accomplished by randomizing subjects to a ‘tailored strategy’ versus a ‘standard strategy.’ In the tailored strategy, subjects would be screening after randomization to determine the most salient barrier to their adherence, and the first intervention would be chosen based on this. A subject who indicated that the primary reason for lack of adherence is forgetfulness and difficulty staying on schedule, for example, would receive the automated reminder intervention. In the standard strategy, there are again several options. One is that all subjects would receive the same intervention, such as the automated reminder system; a second is that all subjects would receive usual care, making the standard arm a more traditional control group. In either case, randomization will ensure that the intervention groups are comparable; the ‘intervention’ in this case is a choice of different options, rather than the same approach applied to all subjects.</p>
<p>A second and arguably more efficient approach is the implementation of sequential multiple assignment randomized trial (SMART) designs [<xref ref-type="bibr" rid="bibr69-1740774512453520">69</xref><xref ref-type="bibr" rid="bibr70-1740774512453520"/><xref ref-type="bibr" rid="bibr71-1740774512453520"/><xref ref-type="bibr" rid="bibr72-1740774512453520"/>–<xref ref-type="bibr" rid="bibr73-1740774512453520">73</xref>]. This approach has been noted for its affinity with interventions in behavioral health in particular [<xref ref-type="bibr" rid="bibr74-1740774512453520">74</xref>]. In this paradigm, subjects are initially randomized to the first component of a strategy (e.g., lottery-based financial incentives). Subjects who demonstrate adherence at a prespecified assessment time (e.g., 4 weeks after beginning the intervention) continue with their assigned therapy, while nonadherent subjects are rerandomized to a different strategy (e.g., continue with lottery intervention versus switch to automated reminder system). Depending on the number of components of the overall approach, additional randomizations can occur. This approach is appealing for several reasons. First, it allows the same sort of overall comparison of the targeted approach between randomized groups. Second, the additional randomizations allow for further evaluation of additional components of the intervention strategy; we can test, for example, whether the addition of reminders to a financial lottery-based incentive improves outcomes in subjects who are still nonadherent with the lottery alone. This is a valuable addition, because concerns are often raised that it is not the financial component of the intervention that is important but the attentional component. Careful use of a SMART design can address this kind of question. It has been noted that with many treatment options included, the number of hypotheses to be tested can quickly become very large; recent study has focused on the use of machine learning techniques to identify promising treatment strategies [<xref ref-type="bibr" rid="bibr75-1740774512453520">75</xref><xref ref-type="bibr" rid="bibr76-1740774512453520"/>–<xref ref-type="bibr" rid="bibr77-1740774512453520">77</xref>]. Third, these designs mirror what often happens in clinical practice: a clinician will choose what seems to be the best strategy, evaluate progress at regular intervals, and try something else if the first approach proves unsuccessful. This is particularly applicable with interventions based on behavioral economics principles, since in this context the preferred strategy is to use the simplest and most cost-effective approach first, only moving on to more in-depth approaches when these initial attempts fail.</p>
</sec>
</sec>
<sec id="section15-1740774512453520" sec-type="discussion">
<title>Discussion</title>
<p>Optimal design and evaluation of interventions to improve medication adherence in chronic conditions requires synthesis of approaches from diverse disciplines. The fields of psychology and behavioral economics offer insights that can improve the design and implementation of interventions, both financial and otherwise, to improve health. Key concepts include contingency management; present-biased preferences and time discounting, in which immediate rewards are weighted more heavily than future gains; loss aversion and regret, in which the loss of something with a certain value is weighted more heavily than the gain of an equivalent amount; variable reinforcement; and overweighting of small probabilities.</p>
<p>Some ethicists have raised concerns about whether financial incentives may be coercive, especially for lower income patients, and about fairness when applied within a heterogeneous population [<xref ref-type="bibr" rid="bibr78-1740774512453520">78</xref>]. Others, however, have argued persuasively that rather than being unjust inducements, incentives can instead be a useful tool with which to steer individuals toward healthy choices without actually restricting choice and may be most effective among patients who struggle to attain desirable health goals by other means [<xref ref-type="bibr" rid="bibr79-1740774512453520">79</xref>].</p>
<p>Regardless of the strategies used to improve medication adherence, both targeting of patient populations and tailoring of intervention strategies using a variety of approaches are important in generating successful outcomes. SMART designs in particular hold great promise in the area of behavioral interventions for medication adherence in chronic disease.</p>
</sec>
</body>
<back>
<ack>
<p>We wish to thank the organizers of the University of Pennsylvania 2011 Conference on Statistical Issues in Clinical Trials (Emerging Statistical Issues in the Conduct and Monitoring of Clinical Trials) for putting together a stimulating day of discussions and presentations.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This study was supported by the National Institutes of Health via NCI Grant R13-CA132565. The clinical trial was supported by NIH Grant R01-HL090929.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1740774512453520">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gibbons</surname><given-names>RJ</given-names></name>
<name><surname>Abrams</surname><given-names>J</given-names></name>
<name><surname>Chatterjee</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>ACC/AHA 2002 guidelines update for the management of patients with chronic stable angina: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Patients with Chronic Stable Angina)</article-title>. <source>Journal of the American College of Cardiology</source> <year>2003</year>; <volume>41</volume>(<issue>1</issue>): <fpage>159</fpage>-<lpage>68</lpage>.</citation>
</ref>
<ref id="bibr2-1740774512453520">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baigent</surname><given-names>C</given-names></name>
<name><surname>Keech</surname><given-names>A</given-names></name>
<name><surname>Kearney</surname><given-names>PM</given-names></name>
<etal/>
</person-group>. <article-title>Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins</article-title>. <source>Lancet</source> <year>2005</year>; <volume>366</volume>(<issue>9493</issue>): <fpage>1267</fpage>–<lpage>78</lpage>.</citation>
</ref>
<ref id="bibr3-1740774512453520">
<label>3.</label>
<citation citation-type="journal">
<collab>Scandinavian Simvastatin Study Group</collab>. <article-title>Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)</article-title>. <source>Lancet</source> <year>1994</year>; <volume>344</volume>(<issue>8934</issue>): <fpage>1383</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr4-1740774512453520">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sacks</surname><given-names>FM</given-names></name>
<name><surname>Pfeffer</surname><given-names>MA</given-names></name>
<name><surname>Moye</surname><given-names>LA</given-names></name>
<etal/>
</person-group>. <article-title>The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators</article-title>. <source>N Engl J Med</source> <year>1996</year>; <volume>335</volume>(<issue>14</issue>): <fpage>1001</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr5-1740774512453520">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Downs</surname><given-names>JR</given-names></name>
<name><surname>Clearfield</surname><given-names>M</given-names></name>
<name><surname>Weis</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study</article-title>. <source>JAMA</source> <year>1998</year>; <volume>279</volume>(<issue>20</issue>): <fpage>1615</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr6-1740774512453520">
<label>6.</label>
<citation citation-type="journal">
<collab>The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group</collab>. <article-title>Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group</article-title>. <source>N Engl J Med</source> <year>1998</year>; <volume>339</volume>(<issue>19</issue>): <fpage>1349</fpage>–<lpage>57</lpage>.</citation>
</ref>
<ref id="bibr7-1740774512453520">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ridker</surname><given-names>PM</given-names></name>
<name><surname>Danielson</surname><given-names>E</given-names></name>
<name><surname>Fonseca</surname><given-names>FA</given-names></name>
<etal/>
</person-group>. <article-title>Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial</article-title>. <source>Lancet</source> <year>2009</year>; <volume>373</volume>(<issue>9670</issue>): <fpage>1175</fpage>–<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr8-1740774512453520">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jackevicius</surname><given-names>CA</given-names></name>
<name><surname>Mamdani</surname><given-names>M</given-names></name>
<name><surname>Tu</surname><given-names>JV</given-names></name>
</person-group>. <article-title>Adherence with statin therapy in elderly patients with and without acute coronary syndromes</article-title>. <source>JAMA</source> <year>2002</year>; <volume>288</volume>(<issue>4</issue>): <fpage>462</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr9-1740774512453520">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Newby</surname><given-names>LK</given-names></name>
<name><surname>LaPointe</surname><given-names>NM</given-names></name>
<name><surname>Chen</surname><given-names>AY</given-names></name>
<etal/>
</person-group>. <article-title>Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease</article-title>. <source>Circulation</source> <year>2006</year>; <volume>113</volume>(<issue>2</issue>): <fpage>203</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr10-1740774512453520">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Benner</surname><given-names>JS</given-names></name>
<name><surname>Glynn</surname><given-names>RJ</given-names></name>
<name><surname>Mogun</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Long-term persistence in use of statin therapy in elderly patients</article-title>. <source>JAMA</source> <year>2002</year>; <volume>288</volume>: <fpage>455</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr11-1740774512453520">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gislason</surname><given-names>GH</given-names></name>
<name><surname>Rasmussen</surname><given-names>JN</given-names></name>
<name><surname>Abildstrom</surname><given-names>SZ</given-names></name>
<etal/>
</person-group>. <article-title>Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction</article-title>. <source>Eur Heart J</source> <year>2006</year>; <volume>27</volume>(<issue>10</issue>): <fpage>1153</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr12-1740774512453520">
<label>12.</label>
<citation citation-type="book">
<person-group person-group-type="editor">
<name><surname>Kulkarni</surname><given-names>SP</given-names></name>
<name><surname>Alexander</surname><given-names>KP</given-names></name>
<name><surname>Lytle</surname><given-names>B</given-names></name>
<name><surname>Heiss</surname><given-names>G</given-names></name>
<name><surname>Peterson</surname><given-names>ED</given-names></name>
</person-group>. <article-title>Long-term adherence with cardiovascular drug regimens</article-title>. <source>Am Heart J</source> <year>2006</year>; <volume>151</volume>(<issue>1</issue>): <fpage>185</fpage>–<lpage>91</lpage>.</citation>
</ref>
<ref id="bibr13-1740774512453520">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Simpson</surname><given-names>E</given-names></name>
<name><surname>Beck</surname><given-names>C</given-names></name>
<name><surname>Richard</surname><given-names>H</given-names></name>
<name><surname>Eisenberg</surname><given-names>MJ</given-names></name>
<name><surname>Pilote</surname><given-names>L</given-names></name>
</person-group>. <article-title>Drug prescriptions after acute myocardial infarction: Dosage, compliance, and persistence</article-title>. <source>Am Heart J</source> <year>2003</year>; <volume>145</volume>(<issue>3</issue>): <fpage>438</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr14-1740774512453520">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hudson</surname><given-names>M</given-names></name>
<name><surname>Richard</surname><given-names>H</given-names></name>
<name><surname>Pilote</surname><given-names>L</given-names></name>
</person-group>. <article-title>Parabolas of medication use and discontinuation after myocardial infarction – are we closing the treatment gap?</article-title> <source>Pharmacoepidemiol Drug Saf</source> <year>2007</year>; <volume>16</volume>(<issue>7</issue>): <fpage>773</fpage>–<lpage>85</lpage>.</citation>
</ref>
<ref id="bibr15-1740774512453520">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eagle</surname><given-names>KA</given-names></name>
<name><surname>Kline-Rogers</surname><given-names>E</given-names></name>
<name><surname>Goodman</surname><given-names>SG</given-names></name>
<etal/>
</person-group>. <article-title>Adherence to evidence-based therapies after discharge for acute coronary syndromes: An ongoing prospective, observational study</article-title>. <source>Am J Med</source> <year>2004</year>; <volume>117</volume>(<issue>2</issue>): <fpage>73</fpage>–<lpage>81</lpage>.</citation>
</ref>
<ref id="bibr16-1740774512453520">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ho</surname><given-names>PM</given-names></name>
<name><surname>Magid</surname><given-names>DJ</given-names></name>
<name><surname>Masoudi</surname><given-names>FA</given-names></name>
<name><surname>McClure</surname><given-names>DL</given-names></name>
<name><surname>Rumsfeld</surname><given-names>JS</given-names></name>
</person-group>. <article-title>Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease</article-title>. <source>BMC Cardiovasc Disord</source> <year>2006</year>; <volume>6</volume>: <fpage>48</fpage>.</citation>
</ref>
<ref id="bibr17-1740774512453520">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Blackburn</surname><given-names>DF</given-names></name>
<name><surname>Dobson</surname><given-names>RT</given-names></name>
<name><surname>Blackburn</surname><given-names>JL</given-names></name>
<etal/>
</person-group>. <article-title>Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: A retrospective cohort study</article-title>. <source>Can J Cardiol</source> <year>2005</year>; <volume>21</volume>(<issue>6</issue>): <fpage>485</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr18-1740774512453520">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ho</surname><given-names>PM</given-names></name>
<name><surname>Rumsfeld</surname><given-names>JS</given-names></name>
<name><surname>Masoudi</surname><given-names>FA</given-names></name>
<etal/>
</person-group>. <article-title>Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus</article-title>. <source>Arch Intern Med</source> <year>2006</year>; <volume>166</volume>(<issue>17</issue>): <fpage>1836</fpage>–<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr19-1740774512453520">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wei</surname><given-names>L</given-names></name>
<name><surname>Wang</surname><given-names>J</given-names></name>
<name><surname>Thompson</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Adherence to statin treatment and readmission of patients after myocardial infarction: A six year follow up study</article-title>. <source>Heart</source> <year>2002</year>; <volume>88</volume>(<issue>3</issue>): <fpage>229</fpage>–<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr20-1740774512453520">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wei</surname><given-names>L</given-names></name>
<name><surname>Flynn</surname><given-names>R</given-names></name>
<name><surname>Murray</surname><given-names>GD</given-names></name>
<name><surname>MacDonald</surname><given-names>TM</given-names></name>
</person-group>. <article-title>Use and adherence to beta-blockers for secondary prevention of myocardial infarction: Who is not getting the treatment?</article-title> <source>Pharmacoepidemiol Drug Saf</source> <year>2004</year>; <volume>13</volume>(<issue>11</issue>): <fpage>761</fpage>–<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr21-1740774512453520">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rasmussen</surname><given-names>JN</given-names></name>
<name><surname>Chong</surname><given-names>A</given-names></name>
<name><surname>Alter</surname><given-names>DA</given-names></name>
</person-group>. <article-title>Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction</article-title>. <source>JAMA</source> <year>2007</year>; <volume>297</volume>(<issue>2</issue>): <fpage>177</fpage>–<lpage>86</lpage>.</citation>
</ref>
<ref id="bibr22-1740774512453520">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ho</surname><given-names>PM</given-names></name>
<name><surname>Spertus</surname><given-names>JA</given-names></name>
<name><surname>Masoudi</surname><given-names>FA</given-names></name>
<etal/>
</person-group>. <article-title>Impact of medication therapy discontinuation on mortality after myocardial infarction</article-title>. <source>Arch Intern Med</source> <year>2006</year>; <volume>166</volume>(<issue>17</issue>): <fpage>1842</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr23-1740774512453520">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hyers</surname><given-names>TM</given-names></name>
<name><surname>Agnelli</surname><given-names>G</given-names></name>
<name><surname>Hull</surname><given-names>RD</given-names></name>
<etal/>
</person-group>. <article-title>Antithrombotic therapy for venous thromboembolic disease</article-title>. <source>Chest</source> <year>1998</year>; <volume>114</volume>(<supplement>5 Suppl</supplement>): <fpage>561S</fpage>–<lpage>78S</lpage>.</citation>
</ref>
<ref id="bibr24-1740774512453520">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Laupacis</surname><given-names>A</given-names></name>
<name><surname>Boysen</surname><given-names>G</given-names></name>
<name><surname>Connolly</surname><given-names>S</given-names></name>
<name><surname>Ezekowitz</surname><given-names>M</given-names></name>
<name><surname>Hart</surname><given-names>R</given-names></name>
<name><surname>James</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials</article-title>. <source>Arch Intern Med</source> <year>1994</year>; <volume>154</volume>(<issue>13</issue>): <fpage>1449</fpage>–<lpage>57</lpage>.</citation>
</ref>
<ref id="bibr25-1740774512453520">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Laupacis</surname><given-names>A</given-names></name>
<name><surname>Albers</surname><given-names>G</given-names></name>
<name><surname>Dalen</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Antithrombotic therapy in atrial fibrillation</article-title>. <source>Chest</source> <year>1998</year>; <volume>114</volume>(<supplement>5 Suppl</supplement>): <fpage>579S</fpage>–<lpage>89S</lpage>.</citation>
</ref>
<ref id="bibr26-1740774512453520">
<label>26.</label>
<citation citation-type="book">
<person-group person-group-type="editor">
<name><surname>Petersen</surname><given-names>P</given-names></name>
<name><surname>Boysen</surname><given-names>G</given-names></name>
<name><surname>Godtfredsen</surname><given-names>J</given-names></name>
<name><surname>Andersen</surname><given-names>ED</given-names></name>
<name><surname>Andersen</surname><given-names>B</given-names></name>
</person-group>. <article-title>Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study</article-title>. <source>Lancet</source> <year>1989</year>; <volume>1</volume>(<issue>8631</issue>): <fpage>175</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr27-1740774512453520">
<label>27.</label>
<citation citation-type="journal">
<collab>Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke</collab>. <article-title>EAFT (European Atrial Fibrillation Trial) Study Group</article-title>. <source>Lancet</source> <year>1993</year>; <volume>342</volume>(<issue>8882</issue>): <fpage>1255</fpage>–<lpage>62</lpage>.</citation>
</ref>
<ref id="bibr28-1740774512453520">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gullov</surname><given-names>AL</given-names></name>
<name><surname>Koefoed</surname><given-names>BG</given-names></name>
<name><surname>Petersen</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study</article-title>. <source>Arch Intern Med</source> <year>1998</year>; <volume>158</volume>(<issue>14</issue>): <fpage>1513</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr29-1740774512453520">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chiquette</surname><given-names>E</given-names></name>
<name><surname>Amato</surname><given-names>MG</given-names></name>
<name><surname>Bussey</surname><given-names>HI</given-names></name>
</person-group>. <article-title>Comparison of an anticoagulation clinic with usual medical care: Anticoagulation control, patient outcomes, and health care costs</article-title>. <source>Arch Intern Med</source> <year>1998</year>; <volume>158</volume>(<issue>15</issue>): <fpage>1641</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr30-1740774512453520">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goldhaber</surname><given-names>SZ</given-names></name>
</person-group>. <article-title>Pulmonary embolism</article-title>. <source>N Engl J Med</source> <year>1998</year>; <volume>339</volume>(<issue>2</issue>): <fpage>93</fpage>–<lpage>104</lpage>.</citation>
</ref>
<ref id="bibr31-1740774512453520">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barritt</surname><given-names>DW</given-names></name>
<name><surname>Jordan</surname><given-names>SC</given-names></name>
</person-group>. <article-title>Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial</article-title>. <source>Lancet</source> <year>1960</year>; <volume>1</volume>: <fpage>1309</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr32-1740774512453520">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hirsh</surname><given-names>J</given-names></name>
<name><surname>Fuster</surname><given-names>V</given-names></name>
</person-group>. <article-title>Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association</article-title>. <source>Circulation</source> <year>1994</year>; <volume>89</volume>(<issue>3</issue>): <fpage>1469</fpage>–<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr33-1740774512453520">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brigden</surname><given-names>M</given-names></name>
<name><surname>Kay</surname><given-names>C</given-names></name>
<name><surname>Le</surname><given-names>A</given-names></name>
<name><surname>Graydon</surname><given-names>C</given-names></name>
<name><surname>McLeod</surname><given-names>B</given-names></name>
</person-group>. <article-title>Audit of the frequency and clinical response to excessive oral anticoagulation in an out-patient population</article-title>. <source>Am J Hematol</source> <year>1998</year>; <volume>59</volume>: <fpage>22</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr34-1740774512453520">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kearon</surname><given-names>C</given-names></name>
<name><surname>Gent</surname><given-names>M</given-names></name>
<name><surname>Hirsh</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism</article-title>. <source>N Engl J Med</source> <year>1999</year>; <volume>340</volume>(<issue>12</issue>): <fpage>901</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr35-1740774512453520">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Landefeld</surname><given-names>CS</given-names></name>
<name><surname>Beyth</surname><given-names>RJ</given-names></name>
</person-group>. <article-title>Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention</article-title>. <source>Am J Med</source> <year>1993</year>; <volume>95</volume>(<issue>3</issue>): <fpage>315</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr36-1740774512453520">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McMahan</surname><given-names>DA</given-names></name>
<name><surname>Smith</surname><given-names>DM</given-names></name>
<name><surname>Carey</surname><given-names>MA</given-names></name>
<name><surname>Zhou</surname><given-names>XH</given-names></name>
</person-group>. <article-title>Risk of major hemorrhage for outpatients treated with warfarin</article-title>. <source>J Gen Intern Med</source> <year>1998</year>; <volume>13</volume>(<issue>5</issue>): <fpage>311</fpage>–<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr37-1740774512453520">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Landefeld</surname><given-names>CS</given-names></name>
<name><surname>Goldman</surname><given-names>L</given-names></name>
</person-group>. <article-title>Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy</article-title>. <source>Am J Med</source> <year>1989</year>; <volume>87</volume>(<issue>2</issue>): <fpage>144</fpage>–<lpage>52</lpage>.</citation>
</ref>
<ref id="bibr38-1740774512453520">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Doshi</surname><given-names>JA</given-names></name>
<name><surname>Zhu</surname><given-names>J</given-names></name>
<name><surname>Lee</surname><given-names>B</given-names></name>
<name><surname>Kimmel</surname><given-names>S</given-names></name>
<name><surname>Volpp</surname><given-names>KG</given-names></name>
</person-group>. <article-title>Impact of a prescription copayment increase on lipid lowering medication adherence in Veterans</article-title>. <source>Circulation</source> <year>2009</year>; <volume>119</volume>: <fpage>390</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr39-1740774512453520">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chernew</surname><given-names>ME</given-names></name>
<name><surname>Shah</surname><given-names>MR</given-names></name>
<name><surname>Wegh</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Impact of decreasing copayments on medication adherence within a disease management environment</article-title>. <source>Health Aff</source> <year>2008</year>; <volume>27</volume>(<issue>1</issue>): <fpage>103</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr40-1740774512453520">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chernew</surname><given-names>ME</given-names></name>
<name><surname>Rosen</surname><given-names>AB</given-names></name>
<name><surname>Fendrick</surname><given-names>AR</given-names></name>
</person-group>. <article-title>Value-based insurance design</article-title>. <source>Health Aff</source> <year>2007</year>; <volume>26</volume>(<issue>2</issue>): <fpage>w195</fpage>–<lpage>203</lpage>.</citation>
</ref>
<ref id="bibr41-1740774512453520">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tversky</surname><given-names>A</given-names></name>
<name><surname>Kahneman</surname><given-names>DR</given-names></name>
</person-group>. <article-title>Loss aversion in riskless choice: A reference-dependent model</article-title>. <source>Q J Econ</source> <year>1991</year>; <volume>106</volume>(<issue>4</issue>): <fpage>1039</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr42-1740774512453520">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marcus</surname><given-names>AC</given-names></name>
<name><surname>Kaplan</surname><given-names>CP</given-names></name>
<name><surname>Crane</surname><given-names>LA</given-names></name>
<etal/>
</person-group>. <article-title>Reducing loss-to-follow-up among women with abnormal Pap smears. Results from a randomized trial testing an intensive follow-up protocol and economic incentives</article-title>. <source>Med Care</source> <year>1998</year>; <volume>36</volume>(<issue>3</issue>): <fpage>397</fpage>–<lpage>410</lpage>.</citation>
</ref>
<ref id="bibr43-1740774512453520">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stevens-Simon</surname><given-names>C</given-names></name>
<name><surname>O’Connor</surname><given-names>P</given-names></name>
<name><surname>Bassford</surname><given-names>K</given-names></name>
</person-group>. <article-title>Incentives enhance postpartum compliance among adolescent prenatal patients</article-title>. <source>J Adolesc Health</source> <year>1994</year>; <volume>15</volume>(<issue>5</issue>): <fpage>396</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr44-1740774512453520">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chaisson</surname><given-names>RE</given-names></name>
<name><surname>Keruly</surname><given-names>JC</given-names></name>
<name><surname>McAvinue</surname><given-names>S</given-names></name>
<name><surname>Gallant</surname><given-names>JE</given-names></name>
<name><surname>Moore</surname><given-names>RD</given-names></name>
</person-group>. <article-title>Effects of an incentive and education program on return rates for PPD test reading in patients with HIV infection</article-title>. <source>J Acquir Immune Defic Syndr Hum Retrovirol</source> <year>1996</year>; <volume>11</volume>(<issue>5</issue>): <fpage>455</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr45-1740774512453520">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kane</surname><given-names>RL</given-names></name>
<name><surname>Johnson</surname><given-names>PE</given-names></name>
<name><surname>Town</surname><given-names>RJ</given-names></name>
<name><surname>Butler</surname><given-names>M</given-names></name>
</person-group>. <article-title>A structured review of the effect of economic incentives on consumers’ preventive behavior</article-title>. <source>Am J Prev Med</source> <year>2004</year>; <volume>27</volume>(<issue>4</issue>): <fpage>327</fpage>–<lpage>52</lpage>.</citation>
</ref>
<ref id="bibr46-1740774512453520">
<label>46.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Higgins</surname><given-names>ST</given-names></name>
<name><surname>Silverman</surname><given-names>K</given-names></name>
</person-group>. <source>Motivating Behavior Change among Illicit Drug Abusers: Research on Contingency Management Interventions</source>. <publisher-name>American Psychological Association</publisher-name>, <publisher-loc>Washington, DC</publisher-loc>, <year>1999</year>.</citation>
</ref>
<ref id="bibr47-1740774512453520">
<label>47.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Higgins</surname><given-names>ST</given-names></name>
</person-group>. <article-title>Applying behavioral economics to the challenge of reducing cocaine abuse</article-title>. In <person-group person-group-type="editor">
<name><surname>Chaloupka</surname><given-names>FJ</given-names></name>
<name><surname>Grossman</surname><given-names>M</given-names></name>
<name><surname>Bickel</surname><given-names>WK</given-names></name>
<name><surname>Saffer</surname><given-names>H</given-names></name>
</person-group>. (eds). <source>The Economic Analysis of Substance Use and Abuse</source>. <publisher-name>NBER</publisher-name>, <publisher-loc>Cambridge, MA</publisher-loc>, <year>1999</year>, pp. <fpage>157</fpage>–<lpage>74</lpage>.</citation>
</ref>
<ref id="bibr48-1740774512453520">
<label>48.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Skinner</surname><given-names>BF</given-names></name>
</person-group>. <source>Cumulative Record: A Selection of Papers</source> (<edition>3rd edn</edition>). <publisher-name>Meredith</publisher-name>, <publisher-loc>New York</publisher-loc>, <year>1972</year>.</citation>
</ref>
<ref id="bibr49-1740774512453520">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bains</surname><given-names>N</given-names></name>
<name><surname>Pickett</surname><given-names>W</given-names></name>
<name><surname>Hoey</surname><given-names>J</given-names></name>
</person-group>. <article-title>The use and impact of incentives in population-based smoking cessation programs: A review</article-title>. <source>Am J Health Promo</source> <year>1998</year>; <volume>12</volume>: <fpage>307</fpage>–<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr50-1740774512453520">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zeelenberg</surname><given-names>M</given-names></name>
<name><surname>Pieters</surname><given-names>R</given-names></name>
</person-group>. <article-title>Consequences of regret aversion in real life: The case of the Dutch postcode lottery</article-title>. <source>Organ Behav Hum Dec</source> <year>2004</year>; <volume>93</volume>(<issue>2</issue>): <fpage>155</fpage>–<lpage>68</lpage>.</citation>
</ref>
<ref id="bibr51-1740774512453520">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ainslie</surname><given-names>G</given-names></name>
</person-group>. <article-title>Specious reward: A behavioral theory of impulsiveness and impulse control</article-title>. <source>Psychol Bull</source> <year>1975</year>; <volume>82</volume>: <fpage>463</fpage>–<lpage>96</lpage>.</citation>
</ref>
<ref id="bibr52-1740774512453520">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thaler</surname><given-names>RH</given-names></name>
</person-group>. <article-title>Some empirical evidence on time inconsistency</article-title>. <source>Rev Econ Stud</source> <year>1981</year>; <volume>23</volume>: <fpage>165</fpage>–<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr53-1740774512453520">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Loewenstein</surname><given-names>G</given-names></name>
<name><surname>Prelec</surname><given-names>D</given-names></name>
</person-group>. <article-title>Anomalies in intertemporal choice: Evidence and an interpretation</article-title>. <source>Quart J Econ</source> <year>1992</year>; <volume>107</volume>: <fpage>573</fpage>–<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr54-1740774512453520">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kirby</surname><given-names>K</given-names></name>
</person-group>. <article-title>Bidding on the future: Evidence against normative discounting of delayed rewards</article-title>. <source>J Exp Psychol Gen</source> <year>1997</year>; <volume>126</volume>: <fpage>54</fpage>–<lpage>70</lpage>.</citation>
</ref>
<ref id="bibr55-1740774512453520">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Camerer</surname><given-names>C</given-names></name>
<name><surname>Ho</surname><given-names>T-H</given-names></name>
</person-group>. <article-title>Experience-weighted attraction learning in normal form games</article-title>. <source>Econometrica</source> <year>1999</year>; <volume>67</volume>: <fpage>837</fpage>–<lpage>74</lpage>.</citation>
</ref>
<ref id="bibr56-1740774512453520">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Loewenstein</surname><given-names>G</given-names></name>
<name><surname>Weber</surname><given-names>EU</given-names></name>
<name><surname>Hsee</surname><given-names>CK</given-names></name>
<name><surname>Welch</surname><given-names>N</given-names></name>
</person-group>. <article-title>Risk as feelings</article-title>. <source>Psychol Bull</source> <year>2001</year>; <volume>127</volume>(<issue>2</issue>): <fpage>267</fpage>–<lpage>86</lpage>.</citation>
</ref>
<ref id="bibr57-1740774512453520">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Connolly</surname><given-names>T</given-names></name>
<name><surname>Butler</surname><given-names>DU</given-names></name>
</person-group>. <article-title>Regret in economic and psychological theories of choice</article-title>. <source>J Behav Dec Making</source> <year>2006</year>; <volume>19</volume>(<issue>2</issue>): <fpage>148</fpage>–<lpage>58</lpage>.</citation>
</ref>
<ref id="bibr58-1740774512453520">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chapman</surname><given-names>GB</given-names></name>
<name><surname>Coups</surname><given-names>EJ</given-names></name>
</person-group>. <article-title>Emotions and preventive health behavior: Worry, regret, and influenza vaccination</article-title>. <source>Health Psychol</source> <year>2006</year>; <volume>25</volume>(<issue>1</issue>): <fpage>82</fpage>–<lpage>90</lpage>.</citation>
</ref>
<ref id="bibr59-1740774512453520">
<label>59.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thaler</surname><given-names>RH</given-names></name>
<name><surname>Tversky</surname><given-names>A</given-names></name>
<name><surname>Kahneman</surname><given-names>AS</given-names></name>
</person-group>. <article-title>The effect of myopia and loss aversion on risk taking: An experimental test</article-title>. <source>Quart J Econ</source> <year>1997</year>; <volume>112</volume>: <fpage>647</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr60-1740774512453520">
<label>60.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rizzo</surname><given-names>JA</given-names></name>
<name><surname>Zeckhauser</surname><given-names>RJ</given-names></name>
</person-group>. <article-title>Reference incomes, loss aversion, and physician behavior</article-title>. <source>Rev Econ Stat</source> <year>2003</year>; <volume>85</volume>(<issue>4</issue>): <fpage>909</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr61-1740774512453520">
<label>61.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Osterberg</surname><given-names>L</given-names></name>
<name><surname>Blaschke</surname><given-names>T</given-names></name>
</person-group>. <article-title>Adherence to medication</article-title>. <source>N Engl J Med</source> <year>2005</year>; <volume>353</volume>(<issue>5</issue>): <fpage>487</fpage>–<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr62-1740774512453520">
<label>62.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haynes</surname><given-names>RB</given-names></name>
<name><surname>Wang</surname><given-names>E</given-names></name>
<name><surname>da Mota-Gomes</surname><given-names>M</given-names></name>
</person-group>. <article-title>A critical review of interventions to improve compliance with prescribed medications</article-title>. <source>Pat Educ Counsel</source> <year>1987</year>; <volume>10</volume>: <fpage>155</fpage>–<lpage>66</lpage>.</citation>
</ref>
<ref id="bibr63-1740774512453520">
<label>63.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Epstein</surname><given-names>L</given-names></name>
<name><surname>Cluss</surname><given-names>P</given-names></name>
</person-group>. <article-title>A behavioral medicine perspective on adherence to long-term medical regimens</article-title>. <source>J Consult Clin Psychol</source> <year>1982</year>; <volume>50</volume>: <fpage>950</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr64-1740774512453520">
<label>64.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>A</given-names></name>
</person-group>. <article-title>Noncompliance in community psychiatry: A review of clinical interventions</article-title>. <source>Hosp Com Psych</source> <year>1991</year>; <volume>42</volume>(<issue>3</issue>): <fpage>282</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr65-1740774512453520">
<label>65.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zygmunt</surname><given-names>A</given-names></name>
<name><surname>Olson</surname><given-names>M</given-names></name>
<name><surname>Boyer</surname><given-names>C</given-names></name>
<name><surname>Mechanic</surname><given-names>D</given-names></name>
</person-group>. <article-title>Interventions to improve medication adherence in schizophrenia</article-title>. <source>Am J Psychiatry</source> <year>2002</year>; <volume>159</volume>: <fpage>1653</fpage>–<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr66-1740774512453520">
<label>66.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ruskin</surname><given-names>PE</given-names></name>
<name><surname>Van der Wende</surname><given-names>J</given-names></name>
<name><surname>Clark</surname><given-names>CR</given-names></name>
<etal/>
</person-group>. <article-title>Feasibility of using the Med-eMonitor™ system in the treatment of schizophrenia: A pilot study</article-title>. <source>Drug Infor J</source> <year>2003</year>; <volume>38</volume>: <fpage>1</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr67-1740774512453520">
<label>67.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Prochaska</surname><given-names>JO</given-names></name>
<name><surname>Butterworth</surname><given-names>S</given-names></name>
<name><surname>Redding</surname><given-names>CA</given-names></name>
<etal/>
</person-group>. <article-title>Initial efficacy of MI, TTM tailoring and HRI’s with multiple behaviors for employee health promotion</article-title>. <source>Prev Med</source> <year>2008</year>; <volume>46</volume>(<issue>3</issue>): <fpage>226</fpage>–<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr68-1740774512453520">
<label>68.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Greene</surname><given-names>GW</given-names></name>
<name><surname>Rossi</surname><given-names>SR</given-names></name>
<name><surname>Rossi</surname><given-names>JS</given-names></name>
<etal/>
</person-group>. <article-title>Dietary applications of the stages of change model</article-title>. <source>J Am Diet Assoc</source> <year>1999</year>; <volume>99</volume>(<issue>6</issue>): <fpage>673</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr69-1740774512453520">
<label>69.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Murphy</surname><given-names>SA</given-names></name>
</person-group>. <article-title>An experimental design for the development of adaptive treatment strategies</article-title>. <source>Stat Med</source> <year>2005</year>; <volume>24</volume>(<issue>10</issue>): <fpage>1455</fpage>–<lpage>81</lpage>.</citation>
</ref>
<ref id="bibr70-1740774512453520">
<label>70.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lavori</surname><given-names>PW</given-names></name>
<name><surname>Dawson</surname><given-names>R</given-names></name>
<name><surname>Rush</surname><given-names>AJ</given-names></name>
</person-group>. <article-title>Flexible treatment strategies in chronic disease: Clinical and research implications</article-title>. <source>Biol Psych</source> <year>2000</year>; <volume>48</volume>(<issue>6</issue>): <fpage>605</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr71-1740774512453520">
<label>71.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lavori</surname><given-names>PW</given-names></name>
<name><surname>Dawson</surname><given-names>R</given-names></name>
</person-group>. <article-title>Dynamic treatment regimes: Practical design considerations</article-title>. <source>Clin Trials</source> <year>2004</year>; <volume>1</volume>(<issue>1</issue>): <fpage>9</fpage>–<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr72-1740774512453520">
<label>72.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Murphy</surname><given-names>SA</given-names></name>
<name><surname>van der Laan</surname><given-names>MJ</given-names></name>
<name><surname>Robins</surname><given-names>JM</given-names></name>
</person-group> and CPPRG. <article-title>Marginal mean models for dynamic regimes</article-title>. <source>JASA</source> <year>2001</year>; <volume>96</volume>: <fpage>1410</fpage>–<lpage>23</lpage>.</citation>
</ref>
<ref id="bibr73-1740774512453520">
<label>73.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bembom</surname><given-names>O</given-names></name>
<name><surname>van der Laan</surname><given-names>MJ</given-names></name>
</person-group>. <article-title>Statistical methods for analyzing sequentially randomized trials</article-title>. <source>J Natl Cancer Inst</source> <year>2007</year>; <volume>99</volume>: <fpage>1577</fpage>–<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr74-1740774512453520">
<label>74.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Collins</surname><given-names>LM</given-names></name>
<name><surname>Murphy</surname><given-names>SA</given-names></name>
<name><surname>Strecher</surname><given-names>V</given-names></name>
</person-group>. <article-title>The multiphase optimization strategy (MOST) and the sequential multiple assignment randomized trial (SMART): New methods for more potent eHealth interventions</article-title>. <source>Am J Prev Med</source> <year>2007</year>; <volume>32</volume>(<supplement>5 Suppl</supplement>): <fpage>S112</fpage>–<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr75-1740774512453520">
<label>75.</label>
<citation citation-type="confproc">
<person-group person-group-type="author">
<name><surname>Deng</surname><given-names>K</given-names></name>
<name><surname>Pineau</surname><given-names>J</given-names></name>
<name><surname>Murphy</surname><given-names>SA</given-names></name>
</person-group>. <article-title>Active learning for developing personalized treatment</article-title>. In <conf-name>Proceedings of the Twenty-Seventh Conference Annual Conference on Uncertainty in Artificial Intelligence (UAI-11)</conf-name>, <conf-loc>Barcelona, Spain</conf-loc>, <conf-date>July 14-17</conf-date>, <publisher-loc>AUAI Press</publisher-loc>: <publisher-name>Corvallis, OR</publisher-name>, <year>2011</year>, pp. <fpage>161</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr76-1740774512453520">
<label>76.</label>
<citation citation-type="confproc">
<person-group person-group-type="author">
<name><surname>Deng</surname><given-names>K</given-names></name>
<name><surname>Pineau</surname><given-names>J</given-names></name>
<name><surname>Murphy</surname><given-names>SA</given-names></name>
</person-group>. <article-title>Active learning for personalizing treatment</article-title>. In <conf-name>2011 IEEE Symposium on Adaptive Dynamic Programming and Reinforcement Learning (ADPRL)</conf-name>, <publisher-loc>IEEE Press</publisher-loc>: <publisher-name>Piscataway, NJ</publisher-name> <conf-date>2011</conf-date>, pp. <fpage>32</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr77-1740774512453520">
<label>77.</label>
<citation citation-type="confproc">
<person-group person-group-type="author">
<name><surname>Lizotte</surname><given-names>D</given-names></name>
<name><surname>Bowling</surname><given-names>M</given-names></name>
<name><surname>Murphy</surname><given-names>SA</given-names></name>
</person-group>. <article-title>Efficient reinforcement learning with multiple reward functions for randomized controlled trial analysis</article-title>. In <conf-name>Proceedings of the 27th International Conference on Machine Learning</conf-name>, <conf-loc>Haifa, Israel</conf-loc>, <conf-date>June 21-24</conf-date>, <publisher-loc>Omnipress</publisher-loc>: <publisher-name>Madison, WI</publisher-name>, <year>2010</year>, pp. <fpage>695</fpage>–<lpage>702</lpage>.</citation>
</ref>
<ref id="bibr78-1740774512453520">
<label>78.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shaw</surname><given-names>J</given-names></name>
</person-group>. <article-title>Is it acceptable for people to be paid to adhere to medication? No</article-title>. <source>BMJ</source> <year>2007</year>; <volume>335</volume>: <fpage>233</fpage>.</citation>
</ref>
<ref id="bibr79-1740774512453520">
<label>79.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Halpern</surname><given-names>SD</given-names></name>
<name><surname>Madison</surname><given-names>KM</given-names></name>
<name><surname>Volpp</surname><given-names>KG</given-names></name>
</person-group>. <article-title>Patients as mercenaries? The ethics of using financial incentives in the war on unhealthy behaviors</article-title>. <source>Circ Cardiovasc Qual Outcomes</source> <year>2009</year>; <volume>2</volume>: <fpage>514</fpage>–<lpage>6</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>